Sjogren’s syndrome: evolving therapies

Bibliography

• JONSSON R, MOEN K, VESTRHEIM D, SZODORAY P: Current issues in Sjogren's syndrome. Oral Dis. (2002) 8:130.
   PubMed Web of Science ®Google Scholar
• FOX R: Sjogren's Syndrome. In: Primer on the Rheumatic Diseases (Vol. 11.). J Klippel (Ed.), Arthritis Foundation, Atlanta, Georgia, USA (1998):283.
   Google Scholar
• FOX PC, SPEIGHT PM: Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Grit. Rev Oral Biol. Med. (1996) 7:144.
   PubMedGoogle Scholar
• FOX RI: Sjogren's syndrome: current therapies remain inadequate for a common disease. Expert Opin. Investig. Drugs (2000) 9:2007.
   PubMed Web of Science ®Google Scholar
• FOX R: Pathogenesis of Sjogren's syndrome. Clinical Immunology: Principles and Practice (2001):89.1.
   Google Scholar
• BOWMAN SJ, PILLEMER S, JONSSON R et al.: Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford) (2001) 40:1180.
   Google Scholar
• •A standardised set of tools for evaluation of SS are required, particularly for the oral component of the disease.
   Google Scholar
• LEMP MA: Epidemiology and classificationof dry eye. Adv. Esp. Med. Biol. (1998) 438:791.
   PubMed Web of Science ®Google Scholar
• LOCKER D, CLARKE M, PAYNE B: Self-perceived oral health status, psychological well-being, and life satisfaction in an older adult population. j Dent. Res. (2000) 79:970.
   PubMed Web of Science ®Google Scholar
• •Although criteria are available for oral evaluation, they have not yet been tested on SS where a multi-system disease may overwhelm the oral component. Attention to the SF-36 and other scores may be necessary.
   Google Scholar
• ALLISON PJ, LOCKER D, FEINE JS: The relationship between dental status and health-related quality of life in upper aerodigestive tract cancer patients. Oral Oricol (1999) 35:138.
   PubMed Web of Science ®Google Scholar
• ALLEN PF, MCMILLAN AS, WALSHAW D, LOCKER D: A comparison of the validity of generic- and disease-specific measures in the assessment of oral health-related quality of life. Community Dent. Ora] Epidemiol (1999) 27:344.
   PubMed Web of Science ®Google Scholar
• SLADE GD: Assessing change in quality of life using the Oral Health Impact Profile. Community Dent. Oral. Epidemiol (1998) 26:52.
   PubMed Web of Science ®Google Scholar
• FOX PC, CUMMINS MJ, CUMMINS JM: Use of orally administered anhydrous crystalline maltose for relief of dry mouth. Altern Complement. Med. (2001) 7:33.
   PubMed Web of Science ®Google Scholar
• •The mechanical act of chewing is a potent stimulus for salivation. This may provide low-cost methods of stimulation but also makes it difficult to assess the additive effect of administered medication in clinical trials (as a non-captured variable).
   Google Scholar
• HAY KD, THOMSON WM: A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Ora] Surg. Oral. Med. Oral. Pathol Oral. Radio] Eridod. (2002) 93:271.
   PubMed Web of Science ®Google Scholar
• SJOGREN K, RUBEN J, LINGSTROM P, LUNDBERG AB, BIRKHED D: Fluoride and urea chewing gums in an intra-oral experimental caries model. Caries Res. (2002) 36:64.
   PubMed Web of Science ®Google Scholar
• SHIP JA, FOX PC, MICHALEK JE, CUMMINS MJ, RICHARDS AB: Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a Phase II clinical trial. IFN Protocol Study Group. I Interferon Cytokine Res. (1999) 19:943.
   PubMed Web of Science ®Google Scholar
• •A potentially important new therapy. The role of the lozenge placebo was significant.
   Google Scholar
• BARNARD DL: Interferon-alpha. Amarillo Biosciences. Curl: Opiri. Investig. Drugs (2002) 3:693.
   Google Scholar
• ARANGO 0: The use of salivary stimulant pastilles to improve compliance in women taking oxybutinin hydrochloride for detrusor instability. Br I Ural. (1998) 81:652.
   PubMedGoogle Scholar
• UKAI Y, TANIGUCHI N, TAKESHITA K, OGASAWARA T, KIMURA K: Enhancement of salivary secretion by chronic anethole trithione treatment. Arch. Pharmacodyn. Ther. (1988) 294:248.
   PubMedGoogle Scholar
• •The clinical experience with this drug, when available, was not as encouraging as this article.
   Google Scholar
• BEN-MAHDI MH, GOZIN A, DRISS F, ANDRIEU V, CHRISTEN MO, PASQUIER C: Anethole dithiolethione regulates oxidant-induced tyrosine kinase activation in endothelial cells. Aritioxid. Redox Signal (2000) 2:789.
   PubMed Web of Science ®Google Scholar
• CHRISTEN MO: Anethole dithiolethione:biochemical considerations. Methods Enzymol (1995) 252:316.
   PubMed Web of Science ®Google Scholar
• HAMADA T, NAKANE T, KIMURA T: Treatment of xerostomia with the bile secretion-stimulating drug anethole trithione: a clinical trial. Am. j Med. Sd. (1999) 318:146.
   PubMed Web of Science ®Google Scholar
• BAUM BJ, KOK M, TRAN SD, YAMANO S: The impact of gene therapy on dentistry: a revisiting after six years. Am. Dent. Assoc. (2002) 133:35.
   PubMed Web of Science ®Google Scholar
• •The general issue of using gene therapy for symptomatic control of a local problem are interesting. Certainly, research can benefit from the ability to directly deliver genes into a region where the products are easily detected in saliva.
   Google Scholar
• PETRONE D, CONDEMI JJ, FIFE R, GLUCK O, COHEN S, DALGIN P: A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. (2002) 46:748.
   PubMed Web of Science ®Google Scholar
• FOX RI, STERN M, MICHELSON P: Update in Sjogren syndrome [In Process Citation]. Curr: Opiri. Rheumatol (2000) 12: 391.
   PubMed Web of Science ®Google Scholar
• FISHER A, MICHAELSON DM, BRANDEIS R, HARING R, CHAPMAN S, PITTEL Z: M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann. NY Acad. Sci. (2000) 920:315.
   PubMed Web of Science ®Google Scholar
• •The link between ageing, Alzheimer's and SS through function at the level of muscarinic receptors goes well beyond the therapy of dryness.
   Google Scholar
• IWABUCHI Y, MASUHARA T: Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen. Pharmacol (1994) 25:123.
   PubMedGoogle Scholar
• IGA Y, ARISAWA H, OGANE N et al: (+1-) cis 2 methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. fpri. I Pharmacol (1998) 78:373.
   Google Scholar
• ARISAWA H, FUKUI K, IMAI E, FUJISE N, MASUNAGA H: General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects. Armeimittelforschung (2002) 52:225.
   Google Scholar
• DELPORTE C, O'CONNELL BC, HEX et al.: Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc. Natl. Acad. Sci.USA (1997) 94:3268.
   Google Scholar
• KUNERT KS, TISDALE AS, STERN ME, SMITH JA, GIPSON IK: Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch. Ophthalmol (2000) 118:1489.
   PubMed Web of Science ®Google Scholar
• STERN ME, GAO J, SCHWALB TA et al.: Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest. Ophthalmol Vis. Li. (2000) 43:2609.
   Web of Science ®Google Scholar
• •The ocular surface becomes a local wound and an area for topical therapy.
   Google Scholar
• HINGORANI M, CALDER VL, BUCKLEY RJ, LIGHTMAN S: The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest. Ophthalmol Vis. Li. (1999) 40:392.
   PubMed Web of Science ®Google Scholar
• TSUBOTA K, SAITO I, ISHIMARU N, HAYASHI Y: Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model. Invest. Ophthalmol Vis. Li. (1999) 39:1551.
   Web of Science ®Google Scholar
• KAS WAN R: Characteristics of a canine model of KCS: effective treatment with topical cyclosporine. Adv. Exp. Med. Biol. (1994) 350:583.
   PubMedGoogle Scholar
• GUILE SD, INCE F, INGALL AH, KINDON ND, MEGHANI P, MORTIMORE MP: The medicinal chemistry of the P2 receptor family. Prog. Med. Chem. (2001) 38:115.
   PubMedGoogle Scholar
• •The use of agents to stimulate purinogenic receptors is a novel and potentially interesting field, although agents with a longer half-life will be required.
   Google Scholar
• FUJIHARA T, MURAKAMI T, FUJITA H, NAKAMURA M, NAKATA K: Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest. Ophthalmal. Vis. Sci. (2001) 42:96.
   PubMed Web of Science ®Google Scholar
• MUNDASAD MV, NOVACK GD, ALLGOOD VE, EVANS RIVI, GORDEN JC, YERXA BR: Ocular safety of IN5365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. ..J. Ocul. Pharmacal. Ther. (2001) 17:173.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DA, SULLIVAN BD, EVANS JE et al.: Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann. NY Acad. Sci. (2002) 966:211.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DA, WICKHAM LA, ROCHA EM etal.: Androgens and dry eye in Sjogren's syndrome. Ann. NY Acad. Sci. (1999) 876:312.
   PubMed Web of Science ®Google Scholar
• •It is is difficult to predict what the topical effect of androgens will achieve, since the ocular surface is away from the myriad of other hormones in the rest of the body (i.e., when androgens are given systemically) and it is unclear which androgen receptors are locally expressed in the milleau of inflammation.
   Google Scholar
• ARAGONA P, DI STEFANO G, FERRERI F, SPINELLA R, STILO A: Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients. Br Ophthalmal. (2002) 86:879.
   PubMed Web of Science ®Google Scholar
• ROMERO-RANGEL T, STAVROU P, COTTER J, ROSENTHAL P, BALTATZIS S, FOSTER CS: Gas-permeable scleral contact lens therapy in ocular surface disease. Am. j Ophthalmal. (2000) 130:25.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl. I Med. (2002) 346:896.
   PubMed Web of Science ®Google Scholar
• STEINFELD SD, DEMOLS P, SALMON I, KISS R, APPELBOOM T: Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum. (2001) 44:2371.
   PubMed Web of Science ®Google Scholar
• •An expensive therapy that has been dramatic in RA patients. The risks and benefits in SS will be more difficult to determine. However, antiTNF antibodies may provide a 'proof-of-principal' for later drug development.
   Google Scholar
• SKOPOULI FN, JAGIELLO P, TSIFETAKI N, MOUTSOPOULOS HM: Methotrexate in primary Sjogren's syndrome. Clin. Exp. Rheumatal (1996) 14:555.
   PubMed Web of Science ®Google Scholar
• WATTS RA: Musculoskeletal and systemic reactions to biological therapeutic agents. Curl: Opin. Rheumatal. (2000) 12: 49.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEN BW, BARKHOF F, TRUYEN L et al: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 47:1531.
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 53:457.
   Google Scholar
• ALEXANDER EL, MALINOW K, LEJEWSKI JE, JERDAN MS, PROVOST Ti ALEXANDER GE: Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann. Intern. Med. (1986) 104:323.
   PubMed Web of Science ®Google Scholar
• DE BACKER H, DEHAENE I: Central nervous system disease in primary Sjogren's syndrome. Acta Neural Belg. (1995) 95:142.
   Google Scholar
• TROJANO M, PAOLICELLI D: The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. Neural Sci. (2001) 22\(Suppl. 2):598.
   Google Scholar
• JUNG SM, LEE BG, JOH GY, CHA JK,CHUNG WT, KIM KH: Primary Sjogren's syndrome manifested as multiple sclerosis and cutaneous erythematous lesions: a case report. j Korean Med. Sci. (2000) 15:115.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS ET, CUPPS TR etal.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862.
   Google Scholar
• SANDBORN WJ, HANAUER SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inllarnm. Bowel Dis. (1999) 5:119.
   PubMed Web of Science ®Google Scholar
• SKOPOULI FN, DAFNI U, IOANNIDIS JP, MOUTSOPOULOS HM: Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin. Arthritis Rheum. (2000) 29:296.
   PubMed Web of Science ®Google Scholar
• VOULGARELIS M, DAFNI UG, ISENBERG DA, MOUTSOPOULOS HM: Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum. (1999) 42:1765.
   PubMed Web of Science ®Google Scholar
• MARIETTE X: Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk. Lymphoma (1999) 33:93.
   PubMed Web of Science ®Google Scholar
• FOX RI: Sjogren's syndrome. Controversies and progress. Clin. Lab. Med. (1997) 17:431.
   PubMedGoogle Scholar
• BICKSTON SJ, LICHTENSTEIN GR, ARSENEAU KO, COHEN RB, COMINELLI F: The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology (1999) 117:1433.
   PubMed Web of Science ®Google Scholar
• KREMER JM: Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semi]. Arthritis Rheum. (1999) 29:14.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JW, MITAL D, CHONG A et al.: Experiences with leflunomide in solid organ transplantation. Transplantation (2002) 73:358.
   PubMed Web of Science ®Google Scholar
• THOENES G, SITTER T, LANGER K, BARTLETT R, SCHLEYERBACK R: Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int. I Immunapharmacal. (1989) 92:921.
   Google Scholar
• BURKHARDT H, KALDEN JR: Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatal Int. (1997) 17:85.
   PubMed Web of Science ®Google Scholar